Martín M, et al. - Researchers conducted the study for analyzing the incidence and characteristics of persistent alopecia (PA) following adjuvant docetaxel for breast cancer (BC) as well as to test the ability of scalp cooling in prevention. For this investigation, BC patients receiving adjuvant chemotherapy followed or not by endocrine therapy were interviewed in a single institution at 1.5 to 5 years following primary diagnosis searching for PA. They found that adjuvant treatment with docetaxel (CD ≥ 400 mmg/m²) was related to a significant rate of grade 2 PA, leading to wearing a wig, in around 10% of patients. Results of this study suggested that scalp cooling is very effective in preventing this undesirable side effect of docetaxel.